Findings from MOST Trial Presented at ISC24: Blood thinners added to clot-busting medication did not improve stroke outcomes

Researchers presenting preliminary late-breaking science presented on the first day of the American Stroke Association’s International Stroke Conference 2024 reported findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial. The results showed that giving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their outcomes 90 days later.

Related Keywords

United States ,Jordan ,Missouri ,Washington University ,American ,Andrewd Barreto ,Josephp Broderick ,Colinp Derdeyn ,Opeolum Adeoye ,Jamesc Grotta , ,National Institute Of Neurological Disorders ,National Institutes Of Health ,National Institutes Of Health Strokenet ,American Stroke Association International Conference ,National Institutes Of Health Stroke Severity Scale ,Washington University School Of Medicine ,American Stroke Association ,International Stroke Conference ,Multi Arm Optimization ,Stroke Thrombolysis ,Care Distinguished Professor ,Emergency Medicine ,Washington University School ,National Institutes ,Health Stroke Severity Scale ,Health Strokenet ,Jordan Elm ,National Institute ,Neurological Disorders ,